Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of ABP-745 tablets in atherosclerotic cardiovascular disease
CTR20260912Phase 2Active
- Sponsor
- New Element Biopharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ABP-745 in atherosclerotic disease, coronary arteriosclerosis, sponsored by New Element Biopharma. Started Apr 2026; status: active.
02
Drugs
ABP-745
03
Conditions
atherosclerotic diseasecoronary arteriosclerosis
Beyond the preview
Go deeper on CTR20260912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260912.